- Home
- MNPR vs HUMA Comparison
MNPR vs HUMA Comparison
Compare MNPR & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNPR | HUMA |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | 184 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.9M | 308.6M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNPR | HUMA |
|---|---|---|
| Price | $59.35 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $107.00 | $6.19 |
| AVG Volume (30 Days) | 149.2K | ★ 7.6M |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $444.16 |
| Revenue Next Year | N/A | $248.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.18 | $0.55 |
| 52 Week High | $105.00 | $2.84 |
Technical Indicators
Market Signals| Indicator | MNPR | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 45.35 |
| Support Level | $56.02 | $0.89 |
| Resistance Level | $60.67 | $1.28 |
| Average True Range (ATR) | 3.50 | 0.13 |
| MACD | -0.56 | -0.03 |
| Stochastic Oscillator | 15.69 | 12.38 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.